TCRX TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Ionis’ rare neurology drug approved; Pfizer inks an ADC deal Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs. | ||
 TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies. | ||
 Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership? Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive effort with TScan to identify and develop T-cell antigen targets for Crohn's disease. This change may affect Amgen's research pipeline in inflammatory bowel disease and influence its future approach to biotech partnerships. For broader context on the sector, consider exploring other... | ||
 TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Cell and gene therapy manufacturers turn to specialist automation partners These partnerships suggest that automation is becoming a practical priority for the cell and gene therapy industry. | ||